All News
#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst#1774 identified a blood-based immune profile with a machine-learning approach that discriminates PsA from Pso.
➡️↑ proportions of differentiated CD4+CD196+CD183–CD194+ and CD4+CD196–CD183–CD194+ T-cells in PsA
#ACR21 @RheumNow https://t.co/64uhJCd2qo
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Fibromyalgianess Glucocorticoid Persistence in RA Patients: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0120 presented at the #ACR21 annual meeting.
https://t.co/9yOM5rSARv https://t.co/Gq2YxbxkmM
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by #RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Great work from #CATCH cohort. Yes I am biased. @earlyarthritis #ACR21 abst#1661 @RheumNow https://t.co/hogyNEQiWM
Janet Pope Janetbirdope ( View Tweet)
#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
Janet Pope Janetbirdope ( View Tweet)
COVID 19 Poster Review
Abst 0197
Haibel & colleagues performed open label study on IL-1/IL-6 inhibitor combo
- Majority avoided mechanical ventilation (25/31)
- 2 pts died while on ECMO
- CT Chest findings improved 1 month after treatment
#ACR21 @RheumNow https://t.co/CIJR1Tx8St
Akhil Sood MD AkhilSoodMD ( View Tweet)
Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept:
⭐️Seropositivity
⭐️no prior bMDARD use
⭐️low HAQ-DI
⭐️low BMI
Abst#1228 @ACR21 @Rheumnow https://t.co/LRd1HVbm5B
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
CH COVID 19 Poster Review
Abst 0196
Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm
- Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome
#ACR21 @RheumNow https://t.co/hX7bBtrIzT
Akhil Sood MD AkhilSoodMD ( View Tweet)
All for one or one for all? Lumper or splitter? Highlight from #ACR21 was session 6S403 looking at axial involvement in AxSpa vs PsA. I share my thoughts here at https://t.co/i2nDvMklee @RheumNow https://t.co/62tRRiAcUJ
Dr. Antoni Chan synovialjoints ( View Tweet)
Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC
Janet Pope Janetbirdope ( View Tweet)
SLE Panel: Learning about Lupus
Drs. Kathryn Dao, Janet Pope, Yuz Yusof, Bella Mehta and Pedro Castillo discuss lupus-related data presented at #ACR21.
@KDAO2011 @Janetbirdope @Yuz6Yusof @bella_mehta @_Castillo_Pedro
https://t.co/RPl6ZqWS05 https://t.co/mdTyocBbr2
Links:
Dr. John Cush RheumNow ( View Tweet)
Gout being sneaky🧐
Common consult question is "infection or flare?" in patients with gout.
@ACR21 ABS0467 w/ Dr Michael Toprover:
🔸Calibrating DECT for LS-spine in gout patients.
🔹DECT signal = MSU deposition?
🔸Future data on back pain/gout flare/MSU🤞?
@RheumaRepublic https://t.co/aDCusqBk8G
Bonnia Liu bonnialiu ( View Tweet)
Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA.
@ACR21 6S403 @RheumNow https://t.co/F73lvpF2at
Pedro Castillo _Castillo_Pedro ( View Tweet)
More thoughts from @ashira_md's talk on Gaslighting/microaggressions from #ACR21 ...
(Q 1/2)
Providers: have you ever been told you are difficult and/or challenging?
Elizabeth Graef SituationRheum ( View Tweet)
Abst 1661
Scheir & colleagues identified patterns of multimorbidity and association w/ disability in patients w/ early RA
- In women: Depression significantly associated w/ disability
- In men: HTN & Lung Disease significantly associated w/ disability
#ACR21 @RheumNow https://t.co/0qkn1TcvOi
Akhil Sood MD AkhilSoodMD ( View Tweet)
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
Janet Pope Janetbirdope ( View Tweet)
#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
Janet Pope Janetbirdope ( View Tweet)
Cycling bDMARDs in #PsA. Law of diminishing returns. The more you fail, the more you cycle BUT can we break cycle by ⬆️adherence & health literacy, d/c smoking, use drug levels, biomarkers. Oh that in in future #ACR meetings! #ACR21 abst#1830 @RheumNow https://t.co/GyhgUGHWe8
Janet Pope Janetbirdope ( View Tweet)